The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05C | Hypnotics and sedatives | |
| 4 | N05CD | Benzodiazepine derivatives | |
| 5 | N05CD14 |
| Active Ingredient | Description | |
|---|---|---|
| Remimazolam |
Remimazolam is an ultra-short acting benzodiazepine sedative. The effects of remimazolam on the CNS are dependent on the dose administered intravenously and presence or absence of other medicinal products. Remimazolam binds to benzodiazepine sites of gamma amino butyric acid type A [GABAA] receptors with high affinity, while its carboxylic acid metabolite (CNS7054) has approximately 300 times lower affinity for these receptors. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BYFAVO Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
| BYFAVO Powder for solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
